Cellbyte, a Munich-based AI-native platform helping pharmaceutical companies accelerate drug launches, has raised $2.75 ...

GSK and the Fleming Initiative have announced six new research programmes to combat antimicrobial resistance (AMR), backed by ...

Biogen has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has ...

Scottish Brain Sciences (SBS) has opened a new clinical research centre at ONE BioHub in Aberdeen, marking a significant step forward in early Alzheimer’s research and trial accessibility across ...

Evotec has received a US$5m milestone payment from Bristol Myers Squibb following the US Food and Drug Administration’s ...

Teva Pharmaceuticals has announced new real-world data showing that AUSTEDO (deutetrabenazine) tablets and AUSTEDO XR ...

Mursla Bio has announced a new collaboration with a leading global pharmaceutical company to support biomarker-guided drug ...

Heidelberg Pharma has reported encouraging progress in its phase 2/2a trial of HDP-101 (INN: pamlectabart tismanitin), its ...

Eisai has presented new clinical data from a post-hoc sub-group analysis of the Clarity AD open-label extension for lecanemab ...

The Christie NHS Foundation Trust has completed a four-month digital transformation project using Netcall’s Liberty Spark to ...

MSD has announced positive results from its phase 3 CORALreef Lipids trial, showing that enlicitide decanoate, an investigational oral PCSK9 inhibitor, significantly reduced low-density lipoprotein ...

Gastro-resistant mercaptamine, marketed as Procysbi, has been accepted for use within NHS Scotland for the treatment of nephropathic cystinosis – a rare, progressive and life-limiting condition ...